Want To Promote Off-Label? Pick Your Battlefield
This article was originally published in Scrip
Executive Summary
US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the FDA's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.
You may also be interested in...
PhRMA/BIO Devise 'Principles' To End Off-Label Limbo
Tired of waiting for safe harbor protections about communicating to payers and prescribers about pharmacoeconomics and unapproved uses, PhRMA and BIO are trying to move discussion forward.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.